


Clinically proven to improve healing of chronic wounds if used earlier in the treatment regime¹

3M™ Promogran™ Protease Modulating Matrix and
3M™ Promogran Prisma™ Wound Balancing Matrix




Why wait?

Start using now and give your patients the best chance.

Chronic wounds can be stalled in the inflammatory phase that leads to delayed healing²

The best way to stimulate wound healing is to:³



This is where 3M™ Promogran™ Matrix Family steps in

Collagen

Collagen is effective at reducing MMP proteases, one of the main causes of inflammation. It also has a positive effect on wound progression.

- Reduces MMPs^{4,*}
- Tissue repair^{5,*}
- Cell growth^{6,7,*}



Oxidized Regenerated Cellulose (ORC)

Cellulose is a major component of plants, once oxidized ORC is completely bioresorbable. ORC may aid wound healing by:

- Reducing protease activity^{9,*}
- Cell growth^{9,*}
- Controlling bacteria growth^{9,*}
- Haemostatic properties^{9,*}

So what are 3M™ Promogran™ Protease Modulating Matrix and 3M™ Promogran Prisma™ Wound Balancing Matrix?

The right balance of materials —
Designed to make a powerful difference:




3M™ Promogran™ Protease
Modulating Matrix
= ORC + Collagen



● 55% Collagen
● 45% ORC

3M™ Promogran Prisma™ Wound
Balancing Matrix
= ORC + Collagen + Silver-ORC



● 55% Collagen
● 44% ORC
● 1% Silver-ORC

What's the difference?

- Promogran Prisma Matrix has **twice the amount** of Collagen/ORC material.
- Promogran Prisma Matrix **contains silver-ORC**, which provides antimicrobial protection against bacteria and infection.^{8,*}

So why wait for a wound to become chronic?





As wounds get older, the chances of the wound healing or improving decreases.¹



Wounds less than 6 months old heal/improve quicker with 3M™ Promogran Prisma™ Wound Balancing Matrix.¹

Early adoption of 3M™ Promogran Prisma™ Wound Balancing Matrix shown to improve healing rates¹

Wound healed/improved¹⁰
Week 4 (p = 0.035)



A 6-week RCT involving DFU patients (n = 40) showed:¹¹


- Significantly more wounds achieved complete healing in the Promogran Matrix Group vs Control Group (63% vs 15%, P < 0.03, or 8.5)

Based on the conditions and outcomes of this study the Promogran Matrix group was statistically 8.5x more likely to heal^{11,8}

8.5x
more likely
to heal


Protect from infection

Wounds withdrawn due to infection¹⁰
Week 12 (p = 0.012)



Increased healing with early treatment¹

Early treatment increased healing by **52%**¹




A prospective randomized multi-center study involving VLU patients (n = 64) showed:¹

87% VLUs < 6 months duration healed or improved in 12 weeks.

Spend less time in hospital¹²

A 6-week RCT (n=40) involving pressure ulcer injuries discovered that patients who used 3M™ Promogran™ Protease Modulating Matrix spent 69% less time in hospital.



Clinically proven for over 18 years!

8.5x

More likely
to heal DFUs¹¹

52%

Increase in healing
rate with early
treatment of VLU¹

90%

Pressure injuries
completely healed¹²

69%

Reduction in
hospital stays¹²

Where can 3M™ Promogran™ Protease Modulating Matrix and 3M™ Promogran Prisma™ Wound Balancing Matrix be used?

Promogran Prisma Matrix is indicated for the management of all wounds healing by secondary intent which are clear of necrotic tissue.

Promogran Matrix and Promogran Prisma Matrix has known haemostatic properties and be used under compression therapy.

Under the supervision of a health care professional, these dressings may be used for the management of the following wound types.



1
Diabetic ulcers



2
Venous ulcers



3
Pressure injuries



4
Ulcers caused by mixed
vascular etiologies



Can be used under
compression therapy
with healthcare
professional
supervision.



No need to remove any
residual dressing during
dressing changes.



Can be cut with sterile
scissors to fit the wound
shape, or it can be pre-
moistened to form a gel
and moulded to fit the
wound.




Ordering information

3M™ Promogran™ Protease Modulating Matrix

| Product code | Dressings per carton | Size |
|--------------|----------------------|--------------------|
| M772028 | 10 | 28cm ² |
| M772123 | 10 | 123cm ² |

3M™ Promogran Prisma™ Wound Balancing Matrix

| Product code | Dressings per carton | Size |
|--------------|----------------------|--------------------|
| PS2028 | 10 | 28cm ² |
| PS2123 | 10 | 123cm ² |



To learn more about how 3M™ Promogran™ Protease Modulating Matrix and 3M™ Promogran Prisma™ Wound Balancing Matrix can help manage your patients contact your local representative.

**in vitro* testing §compared with the control group treated with standard of care.

References

1. Cullen B, Gibson M, Nisbet L. Early adoption of collagen/ORC therapies improves clinical outcomes. Poster presented at: World Union of Wound Healing Societies (WUWHS); 2012; Japan.
2. Fletcher J, Chadwick P 2019 Identifying and managing inflammation Wounds UK Made Easy. London.
3. Gibson D, Cullen B, Legerstee R, Harding KG, Schultz G. MMPs Made Easy. Wounds International 2009; Feb 1
4. Schultz GS, Ladwig G, Wysocki A. Extracellular matrix: a review of its roles in acute and chronic wounds. World Wide Wounds 2005; Accessed August 19, 2020. <http://www.worldwidewounds.com/2005/august/Schultz/Extrace-Matric-Acute-Chronic-Wounds.html>
5. Pachence JM. Collagen-based devices for soft tissue repair. J Biomed Mater Res 1996; 33(1): 3–40.
6. Postlewaithe AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II and III collagens and collagen-derived peptides. Proc Nat Acad Sci USA 1978; 75(2): 87–5.
7. Mian M, Beghe F, Mian E. Collagen as a pharmacological approach in wound healing. Int J Tissue React 1992; 14(Suppl): 1–9.
8. Cullen B, Boyle C, Rennison T, Webb Y, Gregory S. ORC/Collagen Matrix Containing Silver Controls Bacterial Bioburden while Retaining Dermal Cell Viability. Poster Presented at WUWHS July 9, 2004; Paris France.
9. Cullen B Underlying biochemistry in non-healing wounds perpetuates chronicity. Wounds International. 2016; 7(4): 18-24.
10. Gottrup F, Cullen B, Karlsmark T, Bischoff-Mikkelsen M, Nisbet L, Gibson M. Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment. Wound Repair Regen. 2013;21(2):216–225.
11. Lazaro-Martinez JL, Garcia-Morales E, Beneit-Montesinos JV, Martinez-de-Jesus F, Aragon-Sanchez FJ. Randomized comparative trial of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers. Cir Esp. 2007;82(1):27–31.
12. Nisi G, Brandi C, Grimaldi L, Calabro M, D'Aniello C. Use of a protease-modulating matrix in the treatment of pressure sores. Chir Ital. 2005;57(4):465–8.

Note: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals.



3M United Kingdom PLC

Charnwood Campus
10 Bakewell Road
Loughborough
LE11 5RB

Phone: +44 (0)1509 611 611
Web: www.3M.co.uk/Medical

3M Ireland Limited

The Iveagh Building
The Park, Carrickmines
D18 X015
Ireland

Phone: +353 (0)1 280 3555
Web: www.3mireland.ie

© 2021 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. Used under license in Canada.
70-2011-8250-1 PRA-PM-EU-00285 (07/21)